N-linked Glycosylation is Essential for Anti-tumor Activities of KIAA1324 in Gastric Cancer
Overview
Authors
Affiliations
KIAA1324 is a transmembrane protein largely reported as a tumor suppressor and favorable prognosis marker in various cancers, including gastric cancer. In this study, we report the role of N-linked glycosylation in KIAA1324 as a functional post-translational modification (PTM). Loss of N-linked glycosylation eliminated the potential of KIAA1324 to suppress cancer cell proliferation and migration. Furthermore, we demonstrated that KIAA1324 undergoes fucosylation, a modification of the N-glycan mediated by fucosyltransferase, and inhibition of fucosylation also significantly suppressed KIAA1324-induced cell growth inhibition and apoptosis of gastric cancer cells. In addition, KIAA1324-mediated apoptosis and tumor regression were inhibited by the loss of N-linked glycosylation. RNA sequencing (RNAseq) analysis revealed that genes most relevant to the apoptosis and cell cycle arrest pathways were modulated by KIAA1324 with the N-linked glycosylation, and Gene Regulatory Network (GRN) analysis suggested novel targets of KIAA1324 for anti-tumor effects in the transcription level. The N-linked glycosylation blockade decreased protein stability through rapid proteasomal degradation. The non-glycosylated mutant also showed altered localization and lost apoptotic activity that inhibits the interaction between GRP78 and caspase 7. These data demonstrate that N-linked glycosylation of KIAA1324 is essential for the suppressive role of KIAA1324 protein in gastric cancer progression and indicates that KIAA1324 may have anti-tumor effects by targeting cancer-related genes with N-linked glycosylation. In conclusion, our study suggests the PTM of KIAA1324 including N-linked glycosylation and fucosylation is a necessary factor to consider for cancer prognosis and therapy improvement.
Implication of protein post translational modifications in gastric cancer.
Song H, Zhang M, Guo C, Guo X, Ma Y, Ma Y Front Cell Dev Biol. 2025; 13:1523958.
PMID: 39968176 PMC: 11833226. DOI: 10.3389/fcell.2025.1523958.
Xie Y, Wu F, Chen Z, Hou Y Biomark Med. 2024; 18(21-22):995-1005.
PMID: 39469853 PMC: 11633390. DOI: 10.1080/17520363.2024.2416887.
The Research Progress of Metformin Regulation of Metabolic Reprogramming in Malignant Tumors.
Sui Q, Yang H, Hu Z, Jin X, Chen Z, Jiang W Pharm Res. 2024; 41(11):2143-2159.
PMID: 39455505 DOI: 10.1007/s11095-024-03783-2.
Dong C, Liu Y, Chong S, Zeng J, Bian Z, Chen X Int J Mol Sci. 2024; 25(17).
PMID: 39273449 PMC: 11395112. DOI: 10.3390/ijms25179502.
Lopez-Canovas J, Naranjo-Martinez B, Diaz-Ruiz A Cell Oncol (Dordr). 2024; 48(1):161-182.
PMID: 38990489 PMC: 11850423. DOI: 10.1007/s13402-024-00966-2.